William Blair downgraded Verve Therapeutics (VERV) to Market Perform from Outperform with no price target after Eli Lilly (LLY) announced a definitive agreement to acquire Verve. Lilly will commence a tender offer to acquire all of the outstanding shares of Verve for a purchase price of $10.50 per share in cash, an aggregate of approximately $1B, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 per share.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Morning Movers: Verve skyrockets after deal to be acquired by Eli Lilly
- Video: Verve, solar stocks among major pre-market movers
- Verve Therapeutics Merges with Eli Lilly in Acquisition
- Eli Lilly to acquire Verve Therapeutics for $10.50 per share in cash
- M&A News: Verve Therapeutics Stock (VERV) Rallies 75% on News of Potential Acquisition by Eli Lilly